Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Peptide to Inhibit CD200 for Oncology by OX2 Therapeutics for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Peptide to Inhibit CD200 for Oncology is under clinical development by OX2 Therapeutics and currently in Phase I for Pediatric...
Data Insights
Peptide to Inhibit CD200 for Oncology by OX2 Therapeutics for High-Grade Glioma: Likelihood of Approval
Peptide to Inhibit CD200 for Oncology is under clinical development by OX2 Therapeutics and currently in Phase I for High-Grade...